Ludwig Cancer Research

Ludwig Cancer Research was well represented in a recent Cancer Grand Challenges panel on The Future of Cancer Research, which included CEO and Scientific Director Chi Van Dang, Scientific Advisor Karen Vousden and Ludwig Massachusetts Institute of Technology Co-director Tyler Jacks, #CancerChat

Researchers led by Ludwig University of Lausanne’s Leire Bejarano and Johanna Joyce conducted a searching, comparative analysis of individual cells that compose the blood-brain barrier across healthy brain tissue, high- and low-grade primary brain tumors and brain metastases. They report that alterations in tumor-feeding blood vessels are far more pronounced in metastatic brain tumors than in gliomas, with the former showing higher permeability and interactions with distinct immune cell populations. Their high-resolution vascular atlas lays a foundation for the development of novel vascular- and immune-targeting therapies for brain tumors. https://bit.ly/4bFqwYY

CRISPR-Cas9 gene engineering allows scientists to swiftly and precisely add, modify or replace DNA sequences and entire genes for research or, increasingly, cutting-edge therapies—including cancer immunotherapy. A team led by Ludwig University of Lausanne’s Melita Irving and Bernhard Gentner report here a protocol to more precisely engineer the receptors expressed by T cells to target specific cancer antigens for therapy. Their method, which generated stable and potent therapeutic T cells, meets the stringent (GMP) manufacturing standards required of products destined for clinical use. https://bit.ly/4kyTGx0

Check out the latest issue of eLudwigNews conta.cc/3FsIP7M and sign up for our newsletter to stay up to date on all Ludwig news https://bit.ly/LCRnews

Worried about continued funding for cancer (and other biomedical) research? The American Association for Cancer Research will help you reach your representatives in the U.S. Congress. https://bit.ly/4inD1eb

Our congratulations to Ludwig Harvard Medical School's Bradley Bernstein on his election as Fellow of the Academy of the American Association for Cancer Research in recognition of his "seminal contributions to cancer epigenetics." https://bit.ly/3FjHFv3

Congratulations to Ludwig University of Lausanne’s Douglas Hanahan on being honored with the 2025 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research. His numerous and varied contributions to the field have profoundly influenced our understanding of cancer initiation and progression and opened new approaches to its diagnosis and treatment. https://bit.ly/3DGCnt6

Congratulations to Jeffrey Rathmell on his appointment as Director of Ludwig The University of Chicago Pritzker School of Medicine, beginning July 1! We welcome him to the Ludwig community and look forward to working with him to advance our understanding of cancer and improve its prevention, diagnosis and care.

Ludwig Princeton University Associate Director Eileen White discusses the importance of the clinical component connection of Ludwig’s mission to advance the prevention and control of cancer. #CancerResearch youtu.be/L5xLxO7qAAI

Check out the latest issue of eLudwigNews conta.cc/41ynrGB and sign up for our newsletter to stay up to date on all Ludwig news bit.ly/LCRnews